Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Conversation
The Conversation
Health
Guilherme Pessoa-Amorim, Clinical Research Fellow, University of Oxford

The inside story of Recovery: how the world’s largest COVID-19 trial transformed treatment – and what it could do for other diseases

Recovery team members Mark Campbell, Guilherme Pessoa-Amorim and Leon Peto photographed at the Big Data Institute in Oxford Photograph: Adam Gasson/UKRI, CC BY-SA

Guilherme – June 16, 2020. Evening TV news shows across the world were suddenly opening with the result of our research, and rightly so. Dexamethasone was the first drug to be shown to save the lives of people infected with COVID-19. To a young researcher like me, that day felt like being part of history. It was a gift from the UK to the world.

Two years ago this week, the Recovery trial transformed the care of COVID patients with its dexamethasone announcement. Within four hours, the steroid was included in NHS treatment recommendations. Almost overnight, treatment of COVID patients around the world changed completely. It has been estimated that dexamethasone may have saved a million lives in the first nine months following the announcement.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.